| Quick Answer |
| About two-thirds of lost weight returned within a year of stopping semaglutide in the STEP 1 extension. STEP 4 and STEP 5 show weight holding while treatment continues. Regain is driven by biology, with hunger hormones staying altered after weight loss. Protein, strength training, early tracking and a doctor-planned exit lower the risk. |
The Headline Finding: About Two-Thirds Regained
A year after stopping treatment, the average person had put back about two-thirds of the weight they lost.
Most questions about weight regain after Ozempic lead back to this data. Ozempic is a type 2 diabetes medicine, sold in India in strengths up to 1 mg a week.
The weight-management trials here used semaglutide at 2.4 mg, the dose sold as Wegovy. The molecule and the biology are the same, so anyone looking up Ozempic for weight loss will find the relevant regain evidence in these trials.
That figure comes from the STEP 1 trial extension, which followed 327 adults for 52 weeks after 68 weeks of weekly semaglutide ended. Their diet and activity counselling stopped on the same day.
During treatment they lost 17.3% of body weight on average. Over the following year they regained 11.6 percentage points, finishing 5.6% below where they began.
In everyday terms, someone who started at 90 kg would have reached about 74.5 kg, then drifted back to about 85 kg within twelve months.
Health markers followed the scale. Blood pressure returned to its starting level. Among people who began with prediabetes, 93.6% had normal blood sugar at the end of treatment; a year later, only 43.3% still did.
One detail matters for Indian readers. The extension recruited only from sites in Canada, Germany, Japan, the UK and the US, so these trials carry no Indian regain data.
Treat the numbers as the best available guide for someone in Mumbai or Lucknow, without assuming any one person will match them.
What the STEP Trials Show
Read together, the three trials tell one consistent story: weight stays down while treatment continues and climbs once it stops.
| Trial | What it tested | What happened |
|---|---|---|
| STEP 1 extension | 68 weeks on treatment, then one year off, with lifestyle support also stopped | Lost 17.3%, regained 11.6 points; net 5.6% below baseline at week 120 |
| STEP 4 | 20 weeks on treatment for all, then randomised to continue or switch to placebo for 48 weeks, with lifestyle support throughout | Continuers lost a further 7.9%; switchers regained 6.9% |
| STEP 5 | Two years of continuous weekly treatment versus placebo | 15.2% lower weight at week 104, versus 2.6% on placebo |
STEP 4 is the cleanest test of stopping, because chance decided who stopped. All 803 adults took semaglutide for 20 weeks first and lost an average of 10.6%. Then 268 of them, about one in three, were quietly switched to placebo.
Both groups kept their lifestyle counselling. Those who continued lost a further 7.9% over 48 weeks. Those who stopped regained 6.9%. Good habits, on their own, did not hold the line.
STEP 5 asks the opposite question: what happens if you simply keep going? In this trial of 304 adults, those on weekly treatment for two years were 15.2% lighter than at the start, against 2.6% on placebo.
STEP 5 never studied stopping. Its value here is as the mirror image of the extension: with treatment kept on, the lost weight stayed off across 104 weeks.
Whether to continue, and at what dose, is a decision for the doctor supervising treatment.
Why the Body Regains Weight
The body reads weight loss as a threat and works to reverse it.
After losing weight, it burns slightly fewer calories than its new size would predict (metabolic adaptation). It also turns hunger up, through hormones made in the gut and in fat tissue.
A GLP-1 medicine dampens much of that hunger signal while it is active. Once it is withdrawn, the signal returns at the very point where the body is pushing hardest to regain.
This is also why a weight loss plateau during treatment and regain after it are different problems. A plateau means the body has found a new balance while on treatment. Regain means the force that held the new weight has been withdrawn.
Metabolic adaptation and appetite hormones
The clearest evidence comes from a study that involved no medicine at all.
In a 2011 NEJM study by Sumithran and colleagues, 50 adults started a very low calorie diet and lost an average of 13.5 kg. A year later their leptin, the hormone fat tissue uses to signal stored energy, was still low. Their ghrelin, the stomach’s hunger hormone, was still high.
They also rated themselves hungrier than before they started.
In plain terms, a year after losing weight, their appetite system still behaved as if they were underfed. A GLP-1 medicine turns that signal down while it is taken; the underlying drive stays.
Does Everyone Regain?
No. Two-thirds is an average, and individual results vary widely.
In the STEP 1 extension, 48.2% of people were still at least 5% below their starting weight a year after stopping. At the end of treatment that share had been 86.4%. Many slipped, yet almost half kept a loss large enough to matter for blood sugar and blood pressure.
People who lost the most also regained the most in kilograms. They still ended the year with the largest net loss: those who had lost 20% or more were about 12% below their starting weight at week 120.
A pooled analysis of 37 studies published in early 2026 found the same pattern across weight-loss medicines. Weight crept back by about 0.4 kg a month on average, with a projected return to baseline in roughly 1.7 years.
What no study can do yet is predict which person will hold their loss. That uncertainty is the reason the habits below matter for everyone.
What Reduces the Risk of Regain
Three things carry the most evidence: protecting muscle, planning any change in treatment with a doctor, and catching regain while it is still small.
Protein and strength training
Muscle is the tissue most worth defending, and many Indian bodies start with less of it.
At the same BMI, Indians tend to carry more body fat and less muscle than western people , a pattern doctors call thin-fat. Some of the weight lost on any treatment is muscle, so a body that starts low has less margin to give.
Protein for weight loss is the first lever. The ICMR-INDIAB national diet survey found protein supplies just 12% of daily calories in the average Indian diet, against 62% from carbohydrates.
ICMR-NIN sets the baseline protein needed for healthy adults at 0.83 g per kg of body weight a day. For a 70 kg adult, that is about 58 g, and doctors often aim higher during weight loss. Here is what typical servings contribute:
| Food | Serving | Protein (approx.) |
|---|---|---|
| Cooked dal | 1 katori | 6 to 7 g |
| Paneer | 50 g | about 9 g |
| Egg | 1 whole | about 6 g |
| Dahi | 1 katori | 4 to 5 g |
| Roasted chana | 1 handful (30 g) | 6 to 7 g |
Add all five and the total lands between 31 and 34 g, a little over half the baseline. That gap explains why protein needs planning on an Indian plate.
Exercise is the second lever, and it has the strongest maintenance evidence of anything in this article.
In a 2024 Copenhagen trial published in eClinicalMedicine, adults who first lost weight on an eight-week low calorie diet, then paired a daily GLP-1 medicine with supervised exercise for a year, were 5.1 kg lighter one year after stopping both than those who took the medicine alone. After stopping, the medicine-only group regained more than either exercise group.
That trial used an older, daily GLP-1, so its result is a strong signal for weekly treatments, short of proof. Its authors described the dose as about two hours a week of exercise that leaves you breathing hard.
Two hours a week is four brisk 30-minute walks. Short strength sessions, such as chair squats, wall push-ups or carrying filled water bottles, give the protein a reason to rebuild muscle.
Maintenance dosing
Staying on treatment is the only maintenance approach with randomised trial proof.
STEP 4 and STEP 5 both kept people on the full 2.4 mg dose. Whether a lower or less frequent dose can hold the loss is a fair question with thin evidence so far. Small case series suggest it may, but randomised trials comparing tapering with full-dose maintenance have only recently been registered and have not yet reported results.
Any taper is a clinical call, made against your weight trend, side effects and blood markers, by the doctor who prescribes your treatment.
Tracking and support
Regain is easiest to reverse when it is small, so the aim is to spot it early.
| What to track | How often | Why it helps |
|---|---|---|
| Weight, on the same scale, after waking | Once a week | Shows the trend without daily noise |
| Waist at the navel | Once a month | Tracks abdominal fat; Indian cut-offs are 90 cm for men and 80 cm for women |
| A review trigger agreed with your doctor | Set before the last dose | Turns a few kilos of regain into an appointment |
| Follow-up visits | Continue after stopping | Removing all support at once mirrors the STEP 1 extension, the worst case studied |
Weigh in after the bathroom and before your morning chai, so one week compares fairly with the next.
Maintenance Dose vs Stopping
Every route out of treatment carries a different risk of regain, and the evidence behind each differs sharply.
| Option | What the evidence shows | Confidence |
|---|---|---|
| Continue the full maintenance dose | Weight held or kept falling for up to two years (STEP 4, STEP 5) | Strong: randomised trials |
| Lower or less frequent dose | Small case series suggest weight can hold; randomised trials not yet reported | Low: early data |
| Stop, with structured exercise | Less regain one year later in one trial of an older, daily GLP-1 | Moderate: one trial |
| Stop abruptly, with no plan | About two-thirds of the loss regained within a year (STEP 1 extension) | Strong: consistent across studies |
Side effects, pregnancy plans, other health changes and personal choice are all valid reasons to stop. The safest version of stopping is a planned one, agreed with the doctor supervising your treatment before the last dose.
If You Do Regain
Regaining weight is a medical event to manage. It says nothing about your discipline.
Obesity behaves like high blood pressure: control lasts while treatment lasts. Nobody calls a rising BP reading after stopping tablets a character flaw.
Start by ruling out other causes. A new medicine (some steroids, antidepressants and diabetes drugs can add weight), poor sleep, a thyroid change or a stressful stretch can all play a part.
Go back to protein and strength work before cutting food hard. Crash dieting on a body already primed to regain tends to strip muscle first.
Then talk to your doctor about restarting, adjusting treatment or trying a different approach. Each option needs its own clinical checks.
Two kilos caught in March is far easier to handle than eight discovered at a family function in December.
| Conclusion |
| In the STEP 1 extension, about two-thirds of lost weight returned within a year when treatment and support stopped together. STEP 4 and STEP 5 showed weight holding for as long as treatment continued. Regain reflects biology. Enough protein, regular exercise with strength work, early tracking and an exit planned with your doctor give the best odds of keeping what you lost. |
Frequently Asked Questions
1. How much weight do people regain after stopping?
On average, about two-thirds of the lost weight returns within a year. In the STEP 1 extension, adults who had lost 17.3% regained 11.6 percentage points over 52 weeks off semaglutide. A 2026 pooled analysis of 37 studies projected a return to starting weight in roughly 1.7 years without further treatment.
2. What does the STEP 5 trial data show?
STEP 5 tested two years of continuous weekly semaglutide 2.4 mg against placebo in 304 adults. At 104 weeks, the treated group was 15.2% lighter than at the start, versus 2.6% on placebo. It shows weight holding while treatment continues; it did not study what happens after stopping.
3. Why does the body defend its old weight?
After weight loss, the body burns slightly less energy than expected and raises hunger. Research on diet-led weight loss found leptin stayed low and ghrelin stayed high a full year later. A GLP-1 medicine dampens this hunger while it is active, so the push to regain resurfaces once it stops.
4. Does regain happen to everyone?
No. In the STEP 1 extension, 48.2% of people were still at least 5% below their starting weight a year after stopping. People who lost the most regained the most in kilograms but kept the largest net loss. No test can yet predict who will maintain their loss.
5. What habits reduce the risk of regain?
Regular exercise has the strongest evidence: in one trial, people who exercised alongside a GLP-1 were 5.1 kg lighter a year after stopping than those on the medicine alone. Adequate protein, strength training, weekly weigh-ins, monthly waist checks and a doctor-planned exit add to that.
| Medical Disclaimer |
| This article is for general education and does not replace advice from a qualified doctor. GLP-1 medicines are prescription-only in India and should be started, adjusted or stopped only under medical supervision. Speak to your doctor before changing any medicine, diet or exercise routine. |